IDEXX Laboratories, Inc. $IDXX Shares Bought by California Public Employees Retirement System

California Public Employees Retirement System grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 157,570 shares of the company’s stock after purchasing an additional 9,162 shares during the period. California Public Employees Retirement System owned about 0.20% of IDEXX Laboratories worth $100,670,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $30,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories during the third quarter worth $31,000. Armstrong Advisory Group Inc. grew its position in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the period. Salomon & Ludwin LLC acquired a new stake in IDEXX Laboratories during the third quarter valued at $35,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories in the third quarter valued at $35,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total value of $3,369,657.98. Following the completion of the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at $7,963,334.34. This trade represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president owned 19,899 shares in the company, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,957 shares of company stock valued at $29,862,109 in the last three months. Company insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on IDXX. UBS Group decreased their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. BTIG Research dropped their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, Barclays lowered their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Stock Up 2.2%

IDXX stock opened at $586.37 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a 50-day moving average of $656.25 and a two-hundred day moving average of $666.45. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a market cap of $46.69 billion, a price-to-earnings ratio of 44.86, a PEG ratio of 3.48 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.